We caught up with Rohit Aggarwal to discuss the efficacy and safety of IVIg (Octagam 10%) in patients with active dermatomyositis (Clinical Trial Identifier: NCT02728752). The abstract ‘Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)’ (ABSTRACT NUMBER: 0955) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- Could you tell us a little about dermatomyositis and the unmet needs in its treatment? (0:24)
- What is the role of IV immune globulin (IVIG) in the treatment of dermatomyositis? (1:28)
- What were the aims and design of the ProDERM study? (2:39)
- What were the findings of the study in terms of efficacy, safety and tolerability? (3:50)
- What will be the impact of these findings on clinical practice? (6:27)
Disclosures: Dr. Aggarwal has received consulting fees from various pharmaceutical companies including Octapharma, BMS, Mallinckrodt, Pfizer, Janssen, Abbvie, EMD serono, AstraZeneca, Csl Behring, Kezar, Kyverna, Agrenx, Alexion, Q32, Corbus, BI.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Dermatological Conditions
Brian Kim, EADV 2021: Advances in Therapeutics for Chronic Pruritus
In this interview, we talk with Dr Brian Kim (Washington University School of Medicine, St. Louis, MO, USA) about the current unmet need in the treatment of pruritus and how the therapeutic landscape is changing. His presentation entitled ‘New frontiers in itch therapy‘ was given at the EADV 30th Congress, 29 Sep – 2 Oct […]
Sonja Ständer, EADV 2021: New Therapies for Chronic Pruritus and Prurigo
touchIMMUNOLOGY had the great pleasure of speaking with Prof. Sonja Ständer (University Hospital Münster, Münster, Germany) about new treatments for chronic pruritus and prurigo. Her presentation entitled ‘New treatments for chronic pruritus and prurigo’ was given at the EADV 30th Congress, 29 Sep – 2 Oct. Disclosures: Prof. Sonja Ständer has acted as an investigator […]
Sonja Ständer, EADV 2021: Nemolizumab in the Treatment of Prurigo Nodularis
Prof. Sonja Ständer (University Hospital Münster, Münster, Germany) kindly took the time to speak to us about the health burden of prurigo and recent investigations into the IL-31 targeted therapy, nemolizumab. Her presentation entitled ‘Nemolizumab rapidly relieves itch and sleep disturbances in patients with prurigo nodularis’ was given at the EADV 30th Congress, 29 Sep […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!